findmyKOL

Le Min

Basic profile

Brigham and Women's Hospital

ORCIDNPI
RegionBoston, MA · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Last active 2016findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2012–2016Why? →

Le Min is an Endocrinology/Metabolic physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 62 publications with 3,767 citations (h-index 27).

Overview

Scholarship

indexed output and impact (OpenAlex)
62publications

Distinct works indexed by OpenAlex, matched via ORCID.

3,767citations

Total citations across indexed works.

27h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2012–2016

Federally funded research awards.

View funding

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    63.5%
    RANK Ligand Inhibitor63.5%
    Denosumab100%
    Part B, office-administered18 patients
  • Hormonal (systemic)

    19.1%
    l-Thyroxine15.3%
    Levothyroxine Sodium74%Synthroid23%Levoxyl3%
    Part D<11 patients
    l-Triiodothyronine1.4%
    Liothyronine Sodium100%
    Part D<11 patients

    + 3 more classes in this area

  • Metabolism & gastrointestinal

    8.2%
    Biguanide (metformin)2.4%
    Metformin Hcl54%Metformin Hcl Er47%
    Part D<11 patients
    SGLT2 inhibitor2.2%
    Jardiance72%Farxiga28%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)11.7% facility · 88.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20122016 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”